The FDA approved Cobenfy based on the strength of two Phase 3 clinical trials that showed Cobenfy was effective in controlling schizophrenia indicators including hallucinations and depression-like ...

The FDA has approved Bristol Myers Squibb’s new schizophrenia drug, Cobenfy, the first novel treatment for schizophrenia in over 70 years. Schizophrenia affects nearly 3 million U.S. adults, but ...